ALGS
Aligos Therapeutics, Inc.
$5.28
0.00%
$32.7M
No data for this timeframe.
Vol
Market Cap$32.7M
Cap SizeNano Cap
Analyst ConsensusStrong Buy (92%)
Inst. Holders18 funds
Inst. Value$12.0M
Inst. Activity1 buys / 3 sells
SEC Reports2
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001799448·Prev Close $5.28
Recent Activity
May 27, 2026
Press
Aligos Therapeutics presented 10 posters at the EASL Congress 2026, including new Phase 1 long-term follow-up data for p
Impact 4/10
May 27, 2026
fda
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
<p>SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq
Apr 16, 2026
Press
Aligos Therapeutics announced an exclusive license agreement with Xiamen Amoytop Biotech to develop and commercialize pe
Impact 7/10
Mar 9, 2026
Insider
Aneja Nikhil was granted 9,450 shares
Principal Accounting Officer
Mar 9, 2026
Insider
BLATT LAWRENCE was granted 105,840 shares
President and CEO
Mar 9, 2026
Insider
Calhoun Lesley Ann was granted 37,485 shares
See Remarks
Mar 5, 2026
SEC
Aligos Therapeutics reported financial results for Q4 and full year 2025, showing improved net losses compared to the pr
8-K — Impact 5/10
Feb 28, 2026
SEC
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly increased their posit
INST-CLUSTER — Impact 6/10
Price Targets
$56.29
+966.0% upside
Strong Buy
Current $5.28
Low $20.00
Median $45.00
High $175.00
7 analysts
$20.00
$175.00
Analyst Ratings
3Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 28, 2026 | Lake Street | INITIATE | Buy |
| May 21, 2026 | Cantor Fitzgerald | INITIATE | Overweight |
| Mar 26, 2026 | WestPark Capital | INITIATE | Buy |
| Mar 11, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jan 7, 2026 | UBS | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.25 ▼ -15.1% | $-2.91 — $-0.07 | 18% YoY | 5 |
| Next Q | $-2.28 ▼ -1.5% | $-3.16 — $-0.75 | 25% YoY | 5 |
| Current FY | $-7.11 ▼ -13.3% | $-11.76 — $-2.67 | -190% YoY | 6 |
| Next FY | $-4.00 ▲ +17.5% | $-5.09 — $-3.05 | 44% YoY | 6 |
Latest Reports
NEUTRAL
Press
4/10
Aligos Therapeutics presented 10 posters at the EASL Congress 2026, including new Phase 1 long-term follow-up data for p
May 27, 2026
MIXED
8-K
5/10
Aligos Therapeutics reported financial results for Q4 and full year 2025, showing improved net losses compared to the pr
Mar 5, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutional investors — Morgan Stanley, Wells Fargo, and UBS — significantly increased their posit
Feb 28, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| Alyeska Investment Group, L.P. | $3.1M | — |
| MARSHALL WACE, LLP | $2.0M | — |
| BANK OF AMERICA CORP | $1.7M | DOUBLED |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.3M | — |
| Woodline Partners LP | $1.3M | TRIM |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 9, 2026 | Aneja Nikhil | A | $0.00 |
| Mar 9, 2026 | BLATT LAWRENCE | A | $0.00 |
| Mar 9, 2026 | Calhoun Lesley | A | $0.00 |
| Mar 9, 2026 | Symons Julian | A | $0.00 |
18 institutional holders with $12.0M total value (1,610,743 shares) as of 2026-Q1. Top holders: Alyeska, MARSHALL, BANK. Net selling activity: 3 institutions trimmed/exited vs 1 added.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.P. | 412,000 | $3.1M | 25.6% | — |
| 2 | MARSHALL WACE, LLP | 267,135 | $2.0M | 16.6% | — |
| 3 | BANK OF AMERICA CORP /DE/ | 229,754 | $1.7M | 14.3% | DOUBLED +1652.8% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 178,262 | $1.3M | 11.1% | — |
| 5 | Woodline Partners LP | 177,362 | $1.3M | 11.0% | TRIM -38.7% |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 100,450 | $746.3K | 6.2% | ADD +55.3% |
| 7 | BAKER BROS. ADVISORS LP | 83,055 | $617.1K | 5.2% | — |
| 8 | CITADEL ADVISORS LLC | 54,311 | $403.5K | 3.4% | TRIM -32.2% |
| 9 | VANGUARD FIDUCIARY TRUST CO | 28,437 | $211.3K | 1.8% | — |
| 10 | TWO SIGMA INVESTMENTS, LP | 23,093 | $171.6K | 1.4% | DOUBLED +106.8% |
| 11 | Verition Fund Management LLC | 18,887 | $140.3K | 1.2% | TRIM -73.5% |
| 12 | BlackRock, Inc. | 13,040 | $96.9K | 0.8% | ADD +51.3% |
| 13 | D. E. Shaw & Co., Inc. | 10,978 | $81.6K | 0.7% | — |
| 14 | Rockefeller Capital Management L.P. | 10,000 | $74.3K | 0.6% | DOUBLED +900.0% |
| 15 | ROYAL BANK OF CANADA | 2,125 | $16.0K | 0.1% | NEAR_EXIT -90.8% |
| 16 | Vanguard Global Advisers, LLC | 936 | $7.0K | 0.1% | — |
| 17 | WELLS FARGO & COMPANY/MN | 700 | $5.2K | 0.0% | TRIM -52.7% |
| 18 | MORGAN STANLEY | 218 | $1.6K | 0.0% | NEAR_EXIT -91.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 13,108 | 229,754 | +1652.8% | $1.7M | 2026-Q1 |
| Woodline Partners LP | TRIM | 289,169 | 177,362 | -38.7% | $1.3M | 2026-Q1 |
| Verition Fund Management LLC | TRIM | 71,254 | 18,887 | -73.5% | $140.3K | 2026-Q1 |
| MORGAN STANLEY | NEAR_EXIT | 2,520 | 218 | -91.3% | $1.6K | 2026-Q1 |
| Woodline Partners LP | TRIM | 468,199 | 289,169 | -38.2% | $2.7M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 55,019 | 85,444 | +55.3% | $796.3K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 38,995 | 80,649 | +106.8% | $751.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,914 | 13,108 | +584.8% | $122.2K | 2025-Q4 |
| Rockefeller Capital Management L.P. | DOUBLED | 1,000 | 10,000 | +900.0% | $93.2K | 2025-Q4 |
| MORGAN STANLEY | NEAR_EXIT | 11,284 | 2,520 | -77.7% | $23.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | TRIM | 3,170 | 1,500 | -52.7% | $14.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 12,073 | 38,995 | +223.0% | $382.2K | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,743 | 16,182 | +489.9% | $158.6K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 4,005 | 11,284 | +181.7% | $110.6K | 2025-Q3 |
| CITADEL ADVISORS LLC | TRIM | 15,198 | 10,310 | -32.2% | $101.0K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 13,770 | 3,170 | -77.0% | $31.1K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 2,612 | 1,914 | -26.7% | $18.8K | 2025-Q3 |
| Woodline Partners LP | ADD | 315,383 | 518,300 | +64.3% | $3.7M | 2025-Q2 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | TRIM | 465,000 | 140,000 | -69.9% | $1.0M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 39,576 | 52,544 | +32.8% | $378.8K | 2025-Q2 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | DOUBLED | 12,686 | 25,398 | +100.2% | $183.1K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | TRIM | 23,030 | 13,770 | -40.2% | $99.3K | 2025-Q2 |
| UBS Group AG | TRIM | 8,461 | 2,743 | -67.6% | $19.8K | 2025-Q2 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | ADD | 325,000 | 465,000 | +43.1% | $3.8M | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 285 | 154,503 | +54111.6% | $1.3M | 2025-Q1 |
4 unique insiders with 4 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 9, 2026 | Aneja Nikhil | Principal Accounting Officer | AWARD | 9,450 | — | — |
| Mar 9, 2026 | BLATT LAWRENCE | President and CEO | AWARD | 105,840 | — | — |
| Mar 9, 2026 | Calhoun Lesley Ann | See Remarks | AWARD | 37,485 | — | — |
| Mar 9, 2026 | Symons Julian A. | See Remarks | AWARD | 23,310 | — | — |
2 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 5.5/10.
NEUTRAL
4/10
Aligos Therapeutics presented 10 posters at the EASL Congress 2026, including new Phase 1 long-term
May 27, 2026
BULLISH
7/10
Aligos Therapeutics announced an exclusive license agreement with Xiamen Amoytop Biotech to develop
Apr 16, 2026
BULLISH
7/10
Aligos Therapeutics announced FDA Fast Track Designation for pevifoscorvir sodium in chronic HBV inf
Apr 14, 2026
MIXED
6/10
Aligos Therapeutics reported financial results for Q4 and full year 2025, showing a大幅 reduction in n
Mar 5, 2026
Current analyst consensus: Strong Buy (92% buy). Based on 13 analysts: 3 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$56.29 mean target
+966.0% upside
Strong Buy (1.14)
$20.00 Low
$175.00 High
| Metric | Value |
|---|---|
| Current Price | $5.28 |
| Target Low | $20.00 |
| Target Mean | $56.29 |
| Target Median | $45.00 |
| Target High | $175.00 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.14) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.25 | $-2.91 | $-0.07 | 18.4% | -15.1% | — | $0.0B | 1697.9% | 5 |
| Next Q 2026-09-30 |
$-2.28 | $-3.16 | $-0.75 | 24.9% | -1.5% | 0↑ 1↓ | $0.0B | 8.0% | 5 |
| Current FY 2026-12-31 |
$-7.11 | $-11.76 | $-2.67 | -190.3% | -13.3% | 1↑ 1↓ | $0.0B | 891.6% | 6 |
| Next FY 2027-12-31 |
$-4.00 | $-5.09 | $-3.05 | 43.8% | +17.5% | 0↑ 1↓ | $0.0B | -76.9% | 6 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.249 | |
| 7d ago | $-1.544 | +0.295 |
| 30d ago | $-1.085 | -0.164 |
| 60d ago | $-2.270 | +1.021 |
| 90d ago | $-1.901 | +0.652 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 4 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 28, 2026 | Lake Street | INITIATE | — | Buy |
| May 21, 2026 | Cantor Fitzgerald | INITIATE | — | Overweight |
| Mar 26, 2026 | WestPark Capital | INITIATE | — | Buy |
| Mar 11, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 7, 2026 | UBS | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 9 | 1 | 0 | 0 | 92% | |
| May 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Mar 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Feb 1, 2026 | 3 | 7 | 1 | 0 | 0 | 91% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 27, 2026
fda
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
<p>SOUTH SAN FRANCISCO, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical compan
May 13, 2026
other
Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
<p>SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical compan
May 7, 2026
earnings_calendar
ALGS Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
earnings_calendar
ALGS Q1 2026 Earnings Scheduled — 2026-05-04
Apr 24, 2026
other
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p>SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage b
Apr 16, 2026
contract
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
<p>SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceu
Apr 16, 2026
short_volume
Short Volume: ALGS — 56.9% short (0.4M / 0.7M)
Short: 421,176 | Exempt: 34,967 | TRF Vol: 740,242 | Short Ratio: 56.9% | Off-exchange volume (dark pool + OTC)
Apr 14, 2026
fda
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation
<p align="left">SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”) a clinical stage
Mar 9, 2026
earnings_calendar
ALGS Q4 2025 Earnings After Market Close — 2026-03-09
Mar 5, 2026
earnings
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results
<p>SOUTH SAN FRANCISCO, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnolog
Mar 5, 2026
earnings_calendar
ALGS Q4 2025 Earnings After Market Close — 2026-03-05